Vyome Holdings, Inc. · NASDAQ:HIND
Vyome — Technical Presentation (February 2026)
15 slides from Vyome's technical presentation, February 2026
Slide 1: VT-1953 in Treating Symptoms of Malignant Fungating Wounds (MFW)
VT-1953 in Treating Symptoms of Malignant Fungating Wounds (MFW) PHASE 2 IST STUDY RESULTS & NEXT STEPS © Vyome Holdings, Inc. February 2026
Slide 2: Vyome Holdings, Inc. forward-looking statements
VYOME HOLDINGS, INC. (“Vyome”) Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,”
Slide 3: Key Takeaways From Phase 2 Study
Key 1 An investigator-initiated Ph2 study to test VT-1953, a topical dual DNA Gyr and MD2/TLR interaction inhibitor, for safety Takeaways and efficacy in treating the symptoms of MFW From Phase 2 2 VT-1953 achieved a significant improvement (P=0.002) in the Study primary endpoint of malodor on Day 1
Slide 4: What is MFW?
What is MFW? MFW is a rare condition seen in ~10% of advanced cancer patients.* Patients suffer from distressing symptoms, including: Malodor (like “rotten meat”**) ~58,0001 New patients/year in US alone An MFW patient from $55,0002 Lifetime value per patient our Phase 2 study Pain *The Microbiome,
Slide 5: Phase 2 IST testing VT-1953 2% gel in MFW
Phase 2 IST testing VT-1953 2% gel in MFW 15 patients with moderate to severe Active arm (VT-1953 b.i.d): 10 patients malodorous MFW Sex: 7 male, 3 female. Age: median 50.5, mean 56, range 37–77) Sex: 10 male, 5 female. Age: median 50, mean Diagnosis counts: Oral/Head and Neck cancer: 7; Breast canc
Slide 6: VT-1953 treatment significantly reduced malodor: primary endpoint
VT-1953 treatment significantly reduced malodor (scored by investigator on Day 14): primary endpoint By Day 14, participants treated with VT-1953 Topical Gel showed a marked improvement, achieving a median score of 4.0 (range 3.0-4.0), whereas the Vehicle group remained unchanged at 1.0 (range 1.0-1
Slide 7: VT-1953 reduces the negative impact of malodor on quality of life: secondary endpoint
VT-1953 reduces the negative impact of malodor on quality of life (patient reported): secondary endpoint Scored on 5 components: Awareness of malodor Concern about malodor noticed by others Reluctance to socialize because of odor Nauseated by the odor Odor affects appetite 5 YES 0 YES 0 (worst) 5 (b
Slide 8: VT-1953 significantly reduced malodor (patient VAS): exploratory endpoint
VT-1953 significantly reduced malodor (scored by patients on VAS Scale): exploratory endpoint Statistical summary of malodor Visual Analog Scale (VAS) scores, evaluated on a 0–10 scale, at baseline (Day 1) to Day 14 for both treatment groups. Patients scored a reduction in malodor with VT-1953, medi
Slide 9: VT-1953 significantly reduced lesion pain: exploratory endpoint
VT-1953 significantly reduced lesion pain (scored by patients on VAS Scale): exploratory endpoint Statistical summary of Malodor Visual Analog Scale (VAS) scores, measured on a 0–10 scale, at Baseline (Day 1) to Day 14 for both treatment groups. Patients treated with VT-1953 reported a statistically
Slide 10: VT-1953 did not significantly reduce exudate: exploratory endpoint
VT-1953 did not significantly reduce exudate: exploratory endpoint At Day 14, the overall median exudate amount remained unchanged compared to baseline A statistically significant difference was observed between treatment groups at Day 14 (p = 0.0268), favoring the VT-1953 Topical Gel group. Within-
Slide 11: VT-1953 significantly improves QoL: exploratory endpoint
VT-1953 significantly improves QoL (patient-reported outcome measures): exploratory endpoint Summary of patient-reported QoL outcomes scored using a 10-point Visual Analog Scale (VAS) Patient-reported Quality of Life (QoL) scores derived from the mean of all QoL components Severe difficulty Median C
Slide 12: VT-1953 did not exhibit any safety signals during the study period
VT-1953 did not exhibit any safety signals during the study period at doses used • No TEAEs reported • No changes in vital signs • No reports of local skin reactions • *Consistent with observations from prior clinical trials with VT-1953 * VT-1953 (2% topical gel) has been studied for safety and eff
Slide 13: Summary
Summary Treatment with VT-1953 for 14 days successfully met its primary endpoint of significantly reducing malodor associated with MFW as scored by investigators. There is consistency between investigator scores (on TELER score) and malodor scored by patients using VAS (exploratory endpoint) Patient
Slide 14: VT-1953 Anticipated Milestones – Key Focus of Vyome
VT-1953 Anticipated Milestones – Key Focus of Vyome The orphan drug designation application for VT-1953 has been filed and discussions regarding CRO estimates ongoing Orphan drug First patient in Phase 3 final designation approval Phase 3 trial readouts Discussions Phase 3 interim with FDA on readou
Slide 15: Vyome Holdings, Inc.
Vyome Holdings, Inc. (“Vyome”) Venkat Nelabhotla, CEO & Co-Founder nvenkat@vyometx.com +1 (973) 832-8147 Suite 400, One Mifflin Place, Harvard Square Cambridge, MA 02138
Vyome Holdings — Technical Presentation (February 2026) on 6ix